![Michael Higgins](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Higgins
Président chez
VOYAGER THERAPEUTICS, INC.
Fortune : 339 397 $ au 30/06/2026
Profil
Michael J.
Higgins is currently Chief Executive Officer & Director at KinDex Pharmaceuticals, Inc. since 2015.
He serves as Chairman at Voyager Therapeutics, Inc. since 2022 and at Pulmatrix, Inc. since 2020.
He is Director at Morgan Stanley Private Equity Access Fund II LP, Sea Pharmaceuticals LLC since 2016, Madauder Therapeutics, Inc. since 2016, Private Equity Access Fund II, and Independent Director at Cyclerion Therapeutics, Inc. since 2023 and Nocion Therapeutics, Inc. since 2020.
Former roles include Director at Pulmatrix Operating Co., Inc. in 2015, Microbia, Inc., Ruthigen, Inc., Independent Director at Genocea Biosciences, Inc. from 2015 to 2022, Independent Director at CAMP4 Therapeutics Corp.
from 2017 to 2026, VP-Corporate Finance & Business Development at Genzyme Corp.
from 1997 to 2003, Chief Operating Officer at Ironwood Pharmaceuticals, Inc. in 2014, Chief Financial Officer at Procept, Inc. from 1992 to 1997, and Chief Financial Officer at Boston Business Journal.
Education includes undergraduate studies at Cornell University and an MBA from Tuck School of Business at Dartmouth.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/04/2026 | 28 739 ( 0,06% ) | 125 589 $ | 30/06/2026 | |
| 09/06/2026 | 31 314 ( 0,05% ) | 109 599 $ | 30/06/2026 | |
| 30/03/2026 | 30 740 ( 0,71% ) | 104 209 $ | 30/06/2026 | |
PULMATRIX INC -.--% | 23/02/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
Postes actifs de Michael Higgins
| Sociétés | Poste | Début |
|---|---|---|
| PULMATRIX, INC. | Président | 21/04/2020 |
| VOYAGER THERAPEUTICS, INC. | Président | 13/06/2019 |
| CYCLERION THERAPEUTICS, INC. | Directeur/Membre du Conseil | 30/11/2023 |
Private Equity Access Fund II
 Private Equity Access Fund II Investment ManagersFinance Acts as Private Equity Fund | Directeur/Membre du Conseil | - |
Nocion Therapeutics, Inc.
 Nocion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops small molecules for nociceptors | Directeur/Membre du Conseil | 01/09/2020 |
Madauder Therapeutics, Inc.
 Madauder Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Provides business services | Directeur/Membre du Conseil | 01/10/2016 |
Morgan Stanley Private Equity Access Fund II LP
 Morgan Stanley Private Equity Access Fund II LP Investment ManagersFinance Functions as a private equity fund | Directeur/Membre du Conseil | - |
Sea Pharmaceuticals LLC
 Sea Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Operates as a neurotherapeutics research and development company | Directeur/Membre du Conseil | 01/01/2016 |
KinDex Pharmaceuticals, Inc.
 KinDex Pharmaceuticals, Inc. BiotechnologyHealth Technology Provides biotechnology services | Directeur Général | 01/02/2015 |
Anciens postes connus de Michael Higgins
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Michael Higgins
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
70
Relations au 1er degré
20
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 20 |
|---|---|
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Ironwood Pharmaceuticals, Inc.
 Ironwood Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets gastrointestinal products | Health Technology |
Pulmatrix Operating Co., Inc.
 Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for respiratory infectious diseases | Health Technology |
Microbia, Inc.
 Microbia, Inc. Pharmaceuticals: MajorHealth Technology Develops microbial manufacturing technologies | Health Technology |
Genocea Biosciences, Inc.
 Genocea Biosciences, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company that discovers and develops novel cancer immunotherapies | Health Technology |
Morgan Stanley Private Equity Access Fund II LP
Morgan Stanley Private Equity Access Fund II LP Investment ManagersFinance Functions as a private equity fund | Finance |
KinDex Pharmaceuticals, Inc.
KinDex Pharmaceuticals, Inc. BiotechnologyHealth Technology Provides biotechnology services | Health Technology |
Procept, Inc.
 Procept, Inc. Pharmaceuticals: MajorHealth Technology Develops manufactures & markets drugs | Health Technology |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tuck School of Business at Dartmouth
 Tuck School of Business at Dartmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ruthigen, Inc.
 Ruthigen, Inc. Pharmaceuticals: MajorHealth Technology Develops inhaled therapies to address serious pulmonary disease | Health Technology |
Voyager Therapeutics, Inc.
 Voyager Therapeutics, Inc. BiotechnologyHealth Technology Develops gene therapies for fatal and debilitating diseases of the central nervous system | Health Technology |
Boston Business Journal
 Boston Business Journal Publishing: Books/MagazinesConsumer Services Operates as a news publication | Consumer Services |
Pulmatrix, Inc.
 Pulmatrix, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for pulmonary disease | Health Technology |
Sea Pharmaceuticals LLC
Sea Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Operates as a neurotherapeutics research and development company | Commercial Services |
Madauder Therapeutics, Inc.
Madauder Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Provides business services | Commercial Services |
Camp4 Therapeutics Corp.
 Camp4 Therapeutics Corp. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that engages in the development of regulatory RNA-based therapeutics | Health Technology |
Cyclerion Therapeutics, Inc.
 Cyclerion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products for serious and orphan diseases | Health Technology |
Private Equity Access Fund II
Private Equity Access Fund II Investment ManagersFinance Acts as Private Equity Fund | Finance |
Nocion Therapeutics, Inc.
Nocion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops small molecules for nociceptors | Health Technology |
